Logo image of CDTX

CIDARA THERAPEUTICS INC (CDTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CDTX - US1717572069 - Common Stock

219.35 USD
-0.2 (-0.09%)
Last: 11/21/2025, 8:16:46 PM
218.202 USD
-1.15 (-0.52%)
After Hours: 11/21/2025, 8:16:46 PM
Fundamental Rating

3

Taking everything into account, CDTX scores 3 out of 10 in our fundamental rating. CDTX was compared to 535 industry peers in the Biotechnology industry. While CDTX has a great health rating, there are worries on its profitability. CDTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CDTX had negative earnings in the past year.
CDTX had a negative operating cash flow in the past year.
CDTX had negative earnings in each of the past 5 years.
In the past 5 years CDTX always reported negative operating cash flow.
CDTX Yearly Net Income VS EBIT VS OCF VS FCFCDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CDTX has a better Return On Assets (-35.62%) than 74.30% of its industry peers.
Looking at the Return On Equity, with a value of -43.74%, CDTX belongs to the top of the industry, outperforming 81.61% of the companies in the same industry.
Industry RankSector Rank
ROA -35.62%
ROE -43.74%
ROIC N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDTX Yearly ROA, ROE, ROICCDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CDTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDTX Yearly Profit, Operating, Gross MarginsCDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDTX has been increased compared to 1 year ago.
Compared to 5 years ago, CDTX has more shares outstanding
Compared to 1 year ago, CDTX has an improved debt to assets ratio.
CDTX Yearly Shares OutstandingCDTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CDTX Yearly Total Debt VS Total AssetsCDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 32.51 indicates that CDTX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 32.51, CDTX belongs to the top of the industry, outperforming 99.25% of the companies in the same industry.
There is no outstanding debt for CDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.51
ROIC/WACCN/A
WACC8.7%
CDTX Yearly LT Debt VS Equity VS FCFCDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.62 indicates that CDTX has no problem at all paying its short term obligations.
The Current ratio of CDTX (4.62) is better than 92.87% of its industry peers.
CDTX has a Quick Ratio of 4.62. This indicates that CDTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CDTX (4.62) is better than 92.87% of its industry peers.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 4.62
CDTX Yearly Current Assets VS Current LiabilitesCDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CDTX have decreased strongly by -70.23% in the last year.
CDTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
CDTX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.85% yearly.
EPS 1Y (TTM)-70.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.53%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.84% on average over the next years. This is quite good.
Based on estimates for the next years, CDTX will show a very strong growth in Revenue. The Revenue will grow by 142.16% on average per year.
EPS Next Y46.62%
EPS Next 2Y14.35%
EPS Next 3Y10.26%
EPS Next 5Y16.84%
Revenue Next Year-100%
Revenue Next 2Y3.32%
Revenue Next 3Y7.59%
Revenue Next 5Y142.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CDTX Yearly Revenue VS EstimatesCDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CDTX Yearly EPS VS EstimatesCDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDTX Price Earnings VS Forward Price EarningsCDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDTX Per share dataCDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y10.26%

More info and screens

0

5. Dividend

5.1 Amount

CDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (11/21/2025, 8:16:46 PM)

After market: 218.202 -1.15 (-0.52%)

219.35

-0.2 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners107.01%
Inst Owner Change27.82%
Ins Owners0.79%
Ins Owner Change0.33%
Market Cap5.56B
Revenue(TTM)N/A
Net Income(TTM)-184.74M
Analysts84
Price Target185.77 (-15.31%)
Short Float %12.75%
Short Ratio2.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.57%
Min EPS beat(2)-125.8%
Max EPS beat(2)18.65%
EPS beat(4)2
Avg EPS beat(4)-24.63%
Min EPS beat(4)-125.8%
Max EPS beat(4)54.07%
EPS beat(8)5
Avg EPS beat(8)-119.11%
EPS beat(12)7
Avg EPS beat(12)-61.98%
EPS beat(16)10
Avg EPS beat(16)-42.61%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)38.32%
PT rev (3m)146.12%
EPS NQ rev (1m)2.58%
EPS NQ rev (3m)4.52%
EPS NY rev (1m)0%
EPS NY rev (3m)10.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.17
P/tB 13.17
EV/EBITDA N/A
EPS(TTM)-11.78
EYN/A
EPS(NY)-7.96
Fwd EYN/A
FCF(TTM)-5.24
FCFYN/A
OCF(TTM)-5.24
OCFYN/A
SpS0
BVpS16.66
TBVpS16.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.62%
ROE -43.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 4.62
Altman-Z 32.51
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)188.62%
Cap/Depr(5y)130.51%
Cap/Sales(3y)3.7%
Cap/Sales(5y)2.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.53%
EPS Next Y46.62%
EPS Next 2Y14.35%
EPS Next 3Y10.26%
EPS Next 5Y16.84%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y3.32%
Revenue Next 3Y7.59%
Revenue Next 5Y142.16%
EBIT growth 1Y-232.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.14%
EBIT Next 3Y-3.52%
EBIT Next 5YN/A
FCF growth 1Y-328.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-332.86%
OCF growth 3YN/A
OCF growth 5YN/A

CIDARA THERAPEUTICS INC / CDTX FAQ

What is the ChartMill fundamental rating of CIDARA THERAPEUTICS INC (CDTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CDTX.


Can you provide the valuation status for CIDARA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CIDARA THERAPEUTICS INC (CDTX). This can be considered as Overvalued.


Can you provide the profitability details for CIDARA THERAPEUTICS INC?

CIDARA THERAPEUTICS INC (CDTX) has a profitability rating of 1 / 10.